AbbVie raised its full-year profit forecast on Friday while downplaying the potential hit some analysts expect it to take from sector-specific import duties that could be imposed by the Trump administration.

AbbVie Inc. raised its profit outlook for the year on better-than-expected sales from newer autoimmune treatments, but warned its forecast doesn’t take into account any potential changes in trade policy.

Key Takeaways AbbVie's first-quarter sales and adjusted earnings per share topped estimates.The drugmaker lifted its full-year adjusted EPS forecast by 10 cents.However, the company noted its business could be impacted by tariffs that President Trump has said he plans to place on the industry.